Infections in implant surgeries represent serious complications, accounting for approximately 20
The incorporation of plant extracts into polymeric matrices represents a promising strategy for the controlled release of bioactive compounds. In this study, the incorporation of chamomile flower extract (CHAM; Matricaria chamomilla L.) into epoxidized natural rubber grafted with hyaluronic acid (ENR-g-HA) at concentrations of 1.0
Textbook Outcome (TO) combines optimal surgical outcomes into a single measure. This study evaluates achievement of TO using a multicenter database, assessing hospital variation, its correlation with early and late results, and refining a tailored definition of Textbook Outcome in Gastric Surgery (TOGS). Data from patients undergoing curative gastrectomy (2011–2020) in Italian centers affiliated to the Italian Gastric Cancer Research Group (GIRCG) were analyzed. TOGS was introduced at the 2024 GIRCG Annual Meeting in Siena (Italy). Among 1988 patients (median age 72 years, BMI 24.9 kg/m2), 1523 underwent surgery in higher-volume centers (≥ 30 cases per year) and 465 in lower-volume centers (15–30 cases per year). TO was achieved in 54.6
Duchenne muscular dystrophy (DMD) is a severe X-linked disorder characterised by dystrophin deficiency, leading to progressive muscle degeneration and reduced life expectancy. Recent studies report neurodevelopmental and psychiatric comorbidities, though their manifestations remain only partially understood. In this multicentre European study, conducted within the Brain Involvement iN Dystrophinopathies (BIND) consortium, we assessed neurobehavioural outcomes in 238 males aged 5–17 years with genetically confirmed DMD, using standardised parent-report questionnaires. Parent-reported symptoms were reviewed and rated by trained clinicians using criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-V1). We compared findings with two UK-based cohorts: (1) children with pathogenic copy number variants (CNVs) from the IMAGINE-ID study [2] (n = 470; matched on sex, chronological age, and parent-estimated mental age), and (2) a male normative population sample [3] (n = 3,851). Clinician-rated Development and Well-Being Assessment (DAWBA) assessments indicated that 21
Tofacitinib, filgotinib, and upadacitinib are Janus kinase inhibitors (JAKis) available for ulcerative colitis (UC) refractory or intolerant to at least one advanced therapy; their comparative effectiveness in clinical practice remains uncertain. We conducted a multicenter retrospective study including adult UC patients initiating tofacitinib, filgotinib, or upadacitinib (September 2020–June 2025). Clinical remission (partial Mayo score ≤ 1), steroid-free clinical remission, biochemical remission, and endoscopic remission (Mayo endoscopic score = 0) were assessed at predefined time-points. Baseline differences were controlled using inverse probability of treatment weighting (IPTW), and time-to-event and longitudinal analyses were performed. After IPTW, the pseudo-population included 627 patients (tofacitinib = 179, filgotinib = 138, upadacitinib = 310). In the weighted cohort, clinical remission probabilities at weeks 8, 24, and 52 were 17.5
